GLAB Stock Overview
A biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Gemina Laboratories Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.90 |
| 52 Week High | CA$0.90 |
| 52 Week Low | CA$0.28 |
| Beta | 0.095 |
| 11 Month Change | 172.73% |
| 3 Month Change | n/a |
| 1 Year Change | 125.00% |
| 33 Year Change | 143.24% |
| 5 Year Change | n/a |
| Change since IPO | 111.76% |
Recent News & Updates
Shareholder Returns
| GLAB | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 57.9% | -2.9% | 2.2% |
| 1Y | 125.0% | -5.4% | 23.4% |
Return vs Industry: GLAB exceeded the Canadian Biotechs industry which returned -8.6% over the past year.
Return vs Market: GLAB exceeded the Canadian Market which returned 23.4% over the past year.
Price Volatility
| GLAB volatility | |
|---|---|
| GLAB Average Weekly Movement | 27.5% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: GLAB's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: GLAB's weekly volatility has increased from 19% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Brian Firth | www.geminalabs.com |
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It is developing respiratory syncytial virus and tuberculosis.
Gemina Laboratories Ltd. Fundamentals Summary
| GLAB fundamental statistics | |
|---|---|
| Market cap | CA$67.12m |
| Earnings (TTM) | -CA$3.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-18.0x
P/E RatioIs GLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAB income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.72m |
| Earnings | -CA$3.72m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.05 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -42.1% |
How did GLAB perform over the long term?
See historical performance and comparison